Edgewise Therapeutics Inc
EWTX13.990USD
-0.320-2.24%
取引時間 （ET）15分遅れの株価
USD0.000前場取引 (ET)
1.33B時価総額
損失額直近12ヶ月PER
四半期
四半期+年間
四半期
年間
YOY
空白行を非表示にする
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
FY2020Q2
FY2020Q1
営業費用
32.24%45.96M
34.49%45.54M
37.28%40.43M
50.39%38.11M
35.20%34.75M
53.37%33.86M
61.27%29.45M
53.65%25.34M
73.37%25.70M
72.20%22.08M
39.66%18.26M
57.66%16.49M
116.22%14.83M
102.11%12.82M
258.93%13.08M
164.34%10.46M
111.11%6.86M
--6.34M
--3.64M
--3.96M
--3.25M
研究 & 開発費
32.73%36.76M
31.38%36.37M
35.47%32.22M
56.86%30.68M
39.33%27.69M
66.65%27.68M
71.20%23.79M
57.71%19.56M
78.68%19.88M
82.79%16.61M
40.63%13.89M
57.77%12.40M
107.54%11.12M
76.84%9.09M
205.13%9.88M
116.02%7.86M
80.65%5.36M
--5.14M
--3.24M
--3.64M
--2.97M
減価償却費、減耗費および償却費
17.12%554.00K
30.23%629.00K
20.04%539.00K
13.21%480.00K
142.56%473.00K
448.86%483.00K
349.00%449.00K
337.11%424.00K
134.94%195.00K
12.82%88.00K
56.25%100.00K
90.20%97.00K
5.06%83.00K
56.00%78.00K
28.00%64.00K
13.33%51.00K
97.50%79.00K
--50.00K
--50.00K
--45.00K
--40.00K
営業利益
-32.24%-45.96M
-34.49%-45.54M
-37.28%-40.43M
-50.39%-38.11M
-35.20%-34.75M
-53.37%-33.86M
-61.27%-29.45M
-53.65%-25.34M
-73.37%-25.70M
-72.20%-22.08M
-39.66%-18.26M
-57.66%-16.49M
-116.22%-14.83M
-102.11%-12.82M
-258.93%-13.08M
-164.34%-10.46M
-111.11%-6.86M
---6.34M
---3.64M
---3.96M
---3.25M
営業外受取（支払）利息純額
営業外受取利息
-17.13%5.16M
58.05%5.88M
68.57%6.30M
70.80%6.61M
117.31%6.23M
39.60%3.72M
389.40%3.74M
812.74%3.87M
1626.51%2.87M
2014.29%2.66M
501.57%764.00K
296.26%424.00K
295.24%166.00K
6200.00%126.00K
12600.00%127.00K
3466.67%107.00K
-33.33%42.00K
--2.00K
--1.00K
--3.00K
--63.00K
税引前利益
-43.03%-40.80M
-31.58%-39.66M
-32.73%-34.13M
-46.71%-31.50M
-24.90%-28.52M
-55.26%-30.14M
-46.95%-25.71M
-33.62%-21.47M
-55.78%-22.84M
-52.92%-19.41M
-35.13%-17.50M
-55.19%-16.07M
-115.11%-14.66M
-100.19%-12.70M
-255.55%-12.95M
-161.84%-10.35M
-113.97%-6.81M
---6.34M
---3.64M
---3.95M
---3.19M
法人税等
----
--0.00
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
税引後利益
-43.03%-40.80M
-31.58%-39.66M
-32.73%-34.13M
-46.71%-31.50M
-24.90%-28.52M
-55.26%-30.14M
-46.95%-25.71M
-33.62%-21.47M
-55.78%-22.84M
-52.92%-19.41M
-35.13%-17.50M
-55.19%-16.07M
-115.11%-14.66M
-100.19%-12.70M
-255.55%-12.95M
-161.84%-10.35M
-113.97%-6.81M
---6.34M
---3.64M
---3.95M
---3.19M
継続事業による純利益
-43.03%-40.80M
-31.58%-39.66M
-32.73%-34.13M
-46.71%-31.50M
-24.90%-28.52M
-55.26%-30.14M
-46.95%-25.71M
-33.62%-21.47M
-55.78%-22.84M
-52.92%-19.41M
-35.13%-17.50M
-55.19%-16.07M
-115.11%-14.66M
-100.19%-12.70M
-255.55%-12.95M
-161.84%-10.35M
-113.97%-6.81M
---6.34M
---3.64M
---3.95M
---3.19M
親会社株主に帰属する当期純利益
-43.03%-40.80M
-31.58%-39.66M
-32.73%-34.13M
-46.71%-31.50M
-24.90%-28.52M
-55.26%-30.14M
-46.95%-25.71M
-33.62%-21.47M
-55.78%-22.84M
-52.92%-19.41M
-35.13%-17.50M
-55.19%-16.07M
-115.11%-14.66M
-100.19%-12.70M
-255.55%-12.95M
-161.84%-10.35M
-113.97%-6.81M
---6.34M
---3.64M
---3.95M
---3.19M
普通株主に帰属する純利益
-43.03%-40.80M
-31.58%-39.66M
-32.73%-34.13M
-46.71%-31.50M
-24.90%-28.52M
-55.26%-30.14M
-46.95%-25.71M
-33.62%-21.47M
-55.78%-22.84M
-52.92%-19.41M
-35.13%-17.50M
-55.19%-16.07M
-115.11%-14.66M
-100.19%-12.70M
-255.55%-12.95M
-161.84%-10.35M
-113.97%-6.81M
---6.34M
---3.64M
---3.95M
---3.19M
基本的1株当たり利益
-31.66%-0.43
10.02%-0.42
10.21%-0.36
0.57%-0.34
9.76%-0.33
-51.79%-0.47
-20.05%-0.41
-4.62%-0.34
-21.99%-0.36
-19.50%-0.31
-28.41%-0.34
-54.05%-0.32
-106.53%-0.30
-92.38%-0.26
-243.27%-0.26
-152.86%-0.21
-113.96%-0.14
---0.13
---0.08
---0.08
---0.07
希薄化後1株当たり利益
-31.66%-0.43
10.02%-0.42
10.21%-0.36
0.57%-0.34
9.76%-0.33
-51.79%-0.47
-20.05%-0.41
-4.62%-0.34
-21.99%-0.36
-19.50%-0.31
-28.41%-0.34
-54.05%-0.32
-106.53%-0.30
-92.38%-0.26
-243.27%-0.26
-152.86%-0.21
-113.96%-0.14
---0.13
---0.08
---0.08
---0.07
1株当たり配当金
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
通貨単位
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
監査意見
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
